Experience
American Regent, Inc.
Pharmacosmos Therapeutics Inc. et al., Pharmacosmos Therapeutics Inc.
Successfully represented American Regent in litigation in the District of New Jersey against Pharmacosmos and their branded drug, Monoferric®, related to American Regent patents covering the use of iron carbohydrate complexes for the treatment of iron deficiency diseases. The case resulted in a favorable settlement for our client. This representation follows successful representation of American Regent in related post-grant review proceeding.
Pharmacosmos Therapeutics Inc. et al., Pharmacosmos Therapeutics Inc. v. American Regent, Inc., PGR2020-00009, PTAB, Judges Tornquist, Franklin, Wisz
American Regent, Inc. v. Pharmacosmos Therapeutics Inc. et al., Pharmacosmos Therapeutics Inc., 3:20-cv-01350, D.N.J., Judges Goodman, Martinotti, Quraishi
Regenxbio, Inc. et al. v. Sarepta Therapeutics, Inc. et al.
Sarepta Therapeutics, Inc. et al.
Vifor (International) AG and American Regent, Inc. v. Mylan Labs. Ltd. et al.
Vifor (International) AG and American Regent, Inc.
Rocket Pharmaceuticals, Inc. v. Lexeo Therapeutics, Inc., et al.
Rocket Pharmaceuticals, Inc.
Sequenom, Inc. et al
Genzyme Corporation v. Sarepta Therapeutics, Inc. et al.
Sarepta Therapeutics, Inc. et al.
Volkswagen Group of America, Inc. et al. v. Arigna Technology Limited
Volkswagen Group of America, Inc. et al.
Mylan Pharmaceuticals Inc. et al. v. Biogen MA Inc. et al.
Biogen MA Inc. et al.
Aerin Medical Inc. et al. v. Neurent Medical Inc. et al.
Aerin Medical Inc. et al.
Uniloc USA, Inc. et al v. Tencent America, LLC
Tencent America LLC
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.